Chardan Capital Markets Starts Catalyst Biosciences (CBIO) at Buy

Chardan Capital Markets initiates coverage on Catalyst Biosciences (NASDAQ: CBIO) with a Buy rating and a price target of $10.00.

Analyst Dr. Madhu Kumar comments on the company's two leading assets: "Catalyst is a hemophilia therapy company with two lead assets: engineered activated factor VII (FVIIa) marzeptacog alfa (MarzAA), for hemophilia with inhibitors; and engineered factor IX (FIX), CB 2679d, for hemophilia B. The phase II/III trial for MarzAA is expected to start in 4Q17, while phase I/II studies for CB 2679d are expected to start in 2Q17."

For an analyst ratings summary and ratings history on Catalyst Biosciences click here. For more ratings news on Catalyst Biosciences click here.

Shares of Catalyst Biosciences closed at $4.29 Friday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Starts Comfort Systems USA (FIX) at Buy